Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo tested to fight Tough-to-Treat prostate cancer

NCT ID NCT04717154

Summary

This study tested whether a combination of two immunotherapy drugs could help control advanced prostate cancer that had stopped responding to standard hormone therapy. It involved 69 men whose cancer had specific genetic features that might make it more responsive to immunotherapy. Participants received the two-drug combination for four cycles, followed by a single drug for up to a year, to see if it could stop or slow the cancer's growth.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Radboudumc

    Nijmegen, Gelderland, 6525GA, Netherlands

Conditions

Explore the condition pages connected to this study.